News

The company’s lead compound ALLN-177, an oral formulation of oxalate decarboxylase, is being developed to treat patients with disorders of oxalate metabolism. Allena Pharmaceuticals COO Louis Brenner said:

Under the terms of the partnership, BIND will use Nanofitins as targeting ligand components for Accurins in immuno-oncology. After the proof-of-concept stage, BIND expects to expand the partnership

The deal expands AMRI’s API development and manufacturing operations as well as its presence in the European community. Euticals manufactures APIs primarily in Italy, Germany, France and the

The results showed a positive numerical but not statistically significant effect of elsiglutide on the primary endpoint, defined as the proportion of patients experiencing a maximum grade =

This follows on previous round of venture capital investment and non-diluted grant funding up to a total amount of US$25 million. This round of financing was led by

Scheduled for completion in 2016, the Carlsbad campus will increase from 44,000 square feet to 65,000 square feet, with 16 modular viral bulk manufacturing cleanroom suites, two fill/finish

Alopecia areata is an autoimmune disease characterized by patchy or widespread hair loss, for which there is significant unmet medical need and currently no FDA-approved treatment. CTP-543 is

The study, dubbed Resorce, enrolled 573 subjects who were randomized 2:1 to receive either regorafenib plus best supportive care (BSC) or placebo plus BSC. Patients were treated with

Based at BioCity, Nottingham, UK, Haemostatix is developing a pipeline of topical products for surgical bleeding. The company has developed a platform that utilizes synthetic peptide-based haemostats to